Page last updated: 2024-11-12
st 1968
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
namitecan: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 10950142 |
CHEMBL ID | 419186 |
SCHEMBL ID | 5065702 |
SCHEMBL ID | 24685130 |
MeSH ID | M0524553 |
Synonyms (24)
Synonym |
---|
CHEMBL419186 |
st-1968 , |
(4s)-11-((e)-((2-aminoethoxy)imino)methyl)-4-ethyl-4-hydroxy-1,12-dihydro-14h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h)-dione |
372105-27-6 |
st 1968 |
x34z8n66t3 , |
namitecan |
unii-x34z8n66t3 |
namitecan [inn] |
st1968 |
namitecan [who-dd] |
SCHEMBL5065702 |
DTXSID90190707 |
HY-14821 |
CS-6708 |
DB12124 |
(19s)-10-[(e)-2-aminoethoxyiminomethyl]-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione |
A936712 |
(4s)-11-{(e)-[(2-aminoethoxy)imino]methyl}-4-ethyl-4-hydroxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione |
MS-27779 |
SCHEMBL24685130 |
292621-05-7 |
(s)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carbaldehyde o-(2-aminoethyl) oxime |
AKOS040742269 |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" This study was initiated to build an integrated pharmacokinetic (PK) and pharmacodynamic (PD) population model of namitecan to guide future clinical development." | ( Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968). Barbieri, P; Cresta, S; Delmonte, A; Fasolo, A; Gallerani, E; Gianni, L; Hess, D; Joerger, M; Pace, S; Sessa, C, 2015) | 0.42 |
"15 l h(-1), with a long terminal half-life of 48 h." | ( Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968). Barbieri, P; Cresta, S; Delmonte, A; Fasolo, A; Gallerani, E; Gianni, L; Hess, D; Joerger, M; Pace, S; Sessa, C, 2015) | 0.42 |
Dosage Studied
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID332046 | Cytotoxicity against human H460 cells | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9 | Synthesis and cytotoxic activity of new 9-substituted camptothecins. |
AID146690 | Cytotoxicity against human non-small-cell lung carcinoma cell line H460 (NSCLC-H460) | 2001 | Journal of medicinal chemistry, Sep-27, Volume: 44, Issue:20 | Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (14)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (35.71) | 29.6817 |
2010's | 9 (64.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 20.07
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.07) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (14.29%) | 5.53% |
Reviews | 1 (7.14%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (78.57%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |